Search
3 articles for “Positron emission tomography (PET)”
-
Neuroimaging in Clinical Trials for Huntington’s Disease: Emerging Research Findings: The Advancement Directions and Implications
Abstract: Neuroimaging is very important in coordinating and conducting Huntington’s disease clinical trials as a tool in selecting patients, managing safety concerns, and assessing the benefits of interventions. This review presents the current uses and potential future uses of structural and functional magnetic resonance imaging (MRI), diffusion imaging, positron emission tomography (PET), proton magnetic resonance spectroscopy (MRS), perfusion imaging, and magneto encephalography (MEG) in HD trials. We describe how these modalities …
Published in International Journal of Brain Sciences · Vol. 2, Issue 2, 2025 · pp. 32–44 Read article
-
Machine Learning in Nuclear Medical Applications: A Review of Research Frontiers
Abstract: Nuclear medicine, encompassing PET, SPECT, and targeted radionuclide therapy, generates high-dimensional, quantitative data uniquely suited for machine learning (ML) analysis. This review synthesizes current research applications of ML across six key domains. Positron emission tomography (PET), single-photon emission computed tomography (SPECT), and targeted radionuclide therapy are examples of nuclear medicine modalities that generate high- dimensional, quantitative datasets that are particularly well-suited for machine learning (ML)-driven analysis. These imaging methods provide …
Published in Journal of Nuclear Engineering & Technology · Vol. 16, Issue 1, 2026 · pp. 19–24 Read article
-
Artificial Intelligence in Early Diagnosis and Personalized Treatment of Alzheimer’s Disease
Abstract: Artificial intelligence (AI) has become a disruptive technology in the medical care industry, with potential solutions to early diagnosis and customized treatment of Alzheimer’s disease (AD), a progressive neurodegenerative disease and the most prevalent cause of dementia globally. Conventional diagnostic techniques, such as cognitive, neuroimaging and biomarker techniques, are usually limited in the ability to detect disease at its most susceptible stage when treatment interventions are most effective. The recent …
Published in International Journal of Brain Sciences · Vol. 3, Issue 2, 2026 · pp. 15–27 Read article